REPRIEVE-Logo-WebREPRIEVE-Logo-WebREPRIEVE-Logo-WebREPRIEVE-Logo-Web
  • About REPRIEVE
    • Our Story
    • Publications
    • In the News
    • Study FAQ
    • REPRIEVE @ CROI 2023
  • Meet Our Team
    • Clinical Coordinating Center (CCC)
    • Data Coordinating Center (DCC)
    • REPRIEVE Site Teams
    • Community Scientific Subcommittee (CSS)
    • REPRIEVE Community Advisory Board (CAB)
    • National Institutes of Health
  • For Participants
    • Statin Use After REPRIEVE
    • Meet REPRIEVE Participants
    • My Matters Blog
    • Participant Newsletter
    • Recursos en Español
      • Preguntas Más Frecuentes
      • Mapa de Centros de Investigación Clínica
      • Gacetilla Para Participantes N° 1
  • Our Sites
  • Site Resources
    • Study Closure FAQ
    • REPRIEVE Site Newsletters
    • Ancillary Studies
  • My Matters Blog
  • Contact Us
✕

Statin Use After REPRIEVE

Participant guidance

Participant Guidance Pamphlet

English
Spanish
Portuguese
Thai
French
French Canadian
Haitian Creole
Xhosa
Zulu
Sesotho

Search

✕
 

Recent News

  • Daily Statin Trial for People With HIV Halted Early for Clear Benefit
    May 3, 2023
  • Statin Reduces Cardiovascular Risk for People With HIV
    April 13, 2023
©2019 | This website, and any related materials applies only to REPRIEVE A5332. See list of participating sites here.